Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential expression of pancreatic cancer PANC1 cells treated with pilocarpine

ABSTRACT: Human Panc1 cells were treated with 1mM Pilocarpine and the differential expression measured by RNASeq

ORGANISM(S): Homo sapiens

PROVIDER: GSE102880 | GEO | 2018/12/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression analysis of Human pancreatic cancer cell line Panc1 pretreated with DMSO and Clofibrate.

Project description:Investigation of whole genome gene expression level changes of Panc1 pretreated with Clofibrate, compared to Panc1 pretreated with DMSO. Compare differentially expressed genes by analyzing mRNA profilings between DMSO and Clofibrate pretreating Panc1 cell.

2015-06-09 | E-GEOD-69650 | biostudies-arrayexpress

microRNAs profiling in hippocampal cells of mouse with Pilocarpine-induced Status Epilepticus (SE)

Project description:SE was induced in mice (NMRI) chemically by a single dose of Pilocarpine (300mg/kg;i.p.). RNA was extracted from the hippocampi of treated and wild-type mice at 24 h and 28 d after induction. microRNA expressions were measured via microarray technology using Exiqon's miCURY™ LNA Arrays.

2014-01-01 | GSE51841 | GEO

microRNAs profiling in hippocampal cells of mouse with Pilocarpine-induced Status Epilepticus (SE)

2014-01-01 | E-GEOD-51841 | biostudies-arrayexpress

Expression analysis of Human pancreatic cancer cell line Panc1 pretreated with DMSO and Clofibrate.

Project description:Investigation of whole genome gene expression level changes of Panc1 pretreated with Clofibrate, compared to Panc1 pretreated with DMSO.

2015-06-09 | GSE69650 | GEO

RNA-seq in pancreatic cancer PANC1 cells

Project description:RNA-seq in pancreatic cancer PANC1 cells

| PRJNA542693 | ENA

Profiling the Panc1 pancreatic cancer cell line following Gemcitabine treatment using single cell RNA sequencing

Project description:Pancreatic ductal adenocarcinoma (PDAC) often presents at late clinical stages, and most patients are managed solely through palliative chemotherapy. With no approved treatment modalities for patients who progress on broad-spectrum chemotherapy, we set to identify druggable targets to prevent or reverse resistance to the first line anti-neoplastic Gemcitabine. In our first experiment, we used the well-established Panc1 cell line as an in vitro model of PDAC. Panc1 cells were incubated with a tolerable dose of Gemcitabine in vitro, and examined alterations in gene expression via single cell RNA sequencing. In our subsequent studies, we incubated Panc1 cells with increasing doses of Gemcitabine for several passages, until viable in approximately 10x the known IC50 value. These cells were designated Panc1-GR. Based on our observations in the prior experiment, Panc1-GR cells were compared to those treated with wither the Calmodulin inhibitor W-7, Calcium chelator BAPTA-AM, or the calcium channel blocker Amlodipine. Through these efforts, we hope to better understand the mechanisms of Gemcitabine resistance in PDAC, as well as introduce new therapeutic strategies to reverse drug resistant phenotypes in the clinic.

2022-03-21 | GSE186960 | GEO

Expression data of Panc1 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.

2021-08-21 | GSE182526 | GEO

Gene expression profiling of PANC1 and BXPC-3 pancreatic cells

Project description:The aim of this study was to characterize the metabolic and gene expression profile of pancreatic cancer cell line like PANC1 and BXPC-3. Furthermore, to assess the effective sensitivity of cancer cell to metabolic targeting in order to predict their response to therapeutic strategies affecting metabolism. Gene expression profile suggested us some pathway involved in metabolic process that could be used, after validation, as in vivo screening for therapeutic sensitivity.

2017-05-09 | E-MTAB-4540 | biostudies-arrayexpress

Transcription profiling of human drug-resistant Panc1/mock cells and Panc1 cells expressing wildtype syk

Project description:We recently identified the nonreceptor tyrosine kinase syk as a tumor suppressor in pancreatic ductal adenocarcinoma cells. Reintroduction of syk into Panc1 cells promoted a more differentiated phenotype and retarded invasion and tumorigenic growth. Gene array analysis identified over 2,000 transcripts differentially expressed at FDR<0.01. Among these were members of the MMP2 axis, which were subsequently shown to regulate Panc1 invasion. Experiment Overall Design: Affymetrix global gene arrays were used to analyse differences in gene expression patterns in Panc1 cells stably reexpressing syk, or vector-only mock controls. RNA was harvested from cells grown under identical conditions in standard culture.

2009-09-18 | E-GEOD-18000 | biostudies-arrayexpress

Gene expression in PANC1 cells treated with Rakicidin

Project description:Gene expression in PANC1 cells treated with Rakicidin

| PRJNA439193 | ENA